ArticleFrontiers in medicine2026
Multicenter study on magnesium isoglycyrrhizinate preventing novel antitumor-induced liver injury in hematological malignancies.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Antineoplastic agents significantly contribute to drug-induced liver injury (DILI). This study evaluates magnesium isoglycyrrhizinate (MgIG) for preventing DILI in hematological malignancy patients receiving novel antitumor therapies. Methods: This multicenter retrospective analysis included hematological malignancy patients treated with hepatoprotective agents across 13 Chinese centers (December 2023-February 2024). Primary outcomes assessed liver injury incidence and severity at 21, 30, and 60 days; secondary outcomes evaluated safety. Results: Propensity score-matched cohorts (MgIG = 324, control = 182) showed balanced baselines. MgIG recipients had higher chemotherapy (91.4 vs. 64.3%, Conclusions: Prophylactic MgIG attenuates antineoplastic therapy-induced ALT/AST/TBiL elevations in hematological malignancies, demonstrating hepatoprotective efficacy. While its impact on overall DILI incidence remains unclear, longitudinal data suggest clinically meaningful mitigation of hepatotoxicity severity in high-risk subgroups during critical phases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.